Teva Pharmaceuticals (NYSE:TEVA) said today that it closed the $675 million cash sale of its Plan B One-Step product and emergency contraception assets to Foundation Consumer Healthcare.
The move is part of Teva’s efforts to restructure its business, narrowing its focus on CNS and respiratory conditions. The company also plans to divest of its oncology and pain businesses in Europe.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva closes Plan B emergency contraception sale in $2.3B restructuring effort appeared first on MassDevice.